$20.9 Billion Deal: Thermo Fisher Scientific Buys PPD
… Thermo Fisher Scientific Acquires PPD …

$20.9 Billion: Thermo Fisher Scientific Buys PPD

Thermo Fisher Scientific’s transformation by acquisition continues

PPD has 30+ years of driving advanced clinical research for its biopharma clients

  • Clinical data analytics and modeling
  • Clinical trial patient recruitment
  • Comprehensive laboratory services
  • Global regulatory consulting and guidance
  • Phase I through Phase IV clinical trials
  • Post-approval data analytics and monitoring
  • Cardiovascular
  • Cell and gene therapy
  • Critical care
  • Dermatology
  • Endocrinology
  • Gastroenterology
  • Hematology
  • Infectious disease
  • Metabolic
  • Nephrology
  • Neuroscience
  • Oncology
  • Ophthalmology
  • Pediatrics
  • Rare diseases
  • Respiratory
  • Rheumatology
  • Urology
  • Vaccines
  • Women’s Healthcare

Thermo Fisher Scientific’s assertive plans for growth and innovation continue

  • Antibodies
  • BioProduction
  • Cell analysis and cell culture
  • Clinical diagnostics
  • Cloning
  • DNA & RNA purification
  • Forensics
  • Polymerase chain reaction (PCR)
  • Protein biology
  • Sequencing
  • Synthetic biology

Thermo Fisher Scientific is on the move clinically and commercially

  • ClinTec International
  • ICON
  • IQVIA
  • LabCorp
  • Parexel
  • PRA Health Sciences
  • Syneos Health
  • Wuxi Apptec